Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is a disease that is not uncommon, but the treatments vary drastically between Eastern and Western countries. In Europe and America, the first line of treatment is systemic therapy such as sorafenib and the surgical treatment is not a recommend option. While an increasing number of studies from China and Japan have suggested that surgical treatment results in better outcomes when compared to transcatheter arterial chemoembolization (TACE), sorafenib, or other nonsurgical treatments, and two classification systems, Japanese Vp classification and Chinese Cheng's classification, were very useful to guide the surgical treatment. We have also found that surgical treatment may be more effective, as we have performed surgical treatment for HCC-PVTT patients over a period of approximately 15 years and achieved good results with the longest surviving time being 13 years and onward. In this study, we review the efficacy and principles of current surgical treatments and introduce our new, more effective surgical technique named "thrombectomy first", which means the tumor thrombus in the main portal vein, the bifurcation or the contralateral portal vein should be removed prior to liver resection. Thus, compression and crushing of PVTT during the operation could be avoided and new intrahepatic Core tip: The treatments for hepatocellular carcinoma with portal vein tumor thrombus between Eastern and Western countries vary drastically. In Western countries, the first-line treatment is systemic therapy such as sorafenib, while studies from China and Japan suggest that surgical treatment results in better outcomes. We review the efficacy and principles of current surgical treatments and introduce our new, more effective surgical technique named "thrombectomy first", which means the tumor thrombus would be removed prior to liver resection. We have performed this technique over approximately 15 years and achieved good results with the longest surviving time being 13 years and onward.
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INTRODUCTION
Portal vein tumor thrombus (PVTT) is not rare, but it is correlated with an extremely poor prognosis, with approximately 40% of patients with hepatocellular car cinoma (HCC) having PVTT when diagnosed [1] . HCC with PVTT is recognized as an advanced stage disease (BCLCC) according to the Barcelona Clinic for Liver Cancer (BCLC) staging system [2] . Surgical resection is not a recommended treatment option; the only proposed treatment option is systemic therapy. The tyrosine kinase inhibitors sorafenib and regorafenib have been reported to prolong survival and have been selected as treatment options [3] . Both the American Association for the Study of the Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) accepted the BCLC treatment algorithm [4, 5] . Eastern countries have totally opposite views. Experts from mainland China [6] and Japan [7] as well as other eas tern experts [8] have recognized that HCC with PVTT is not a contradiction of surgical approach. In selected HCC PVTT patients, surgical treatment could not only improve the life quality but also prolong the survival time, even though a R0 resection for this malignant disease could not be achieved. The criteria for surgical resection are defined as follows: (1 
EFFICACY OF SURGICAL TREATMENT

Surgical vs nonsurgical treatments
A Japanese nationwide survey [9] of 6474 patients from 645 registered institutions showed that the median survival time (MST) of the operation group was prolonged by 1.77 years compared to the nonsurgical group (2.87 years vs 1.10 years; P < 0.001) for the overall cohort and by 0.88 years (2.45 years vs 1.57 years; P < 0.001) for the propensity scorematched cohort. Furthermore, the survival rates at 1, 3, and 5 years after diagnosis for the operation group were significantly higher compared to the conventional treatment group, with the survival rates being 70.9%, 43.5%, and 32.9% compared to 62.9%, 31.6%, and 20.1%, respectively. Moreover, subgroup analysis after propensity score matching re vealed that surgical treatment provided a survival be nefit regardless of age, etiology, serum α-fetoprotein elevation, tumor number, or hepatitis B or C infection; however, a previous study [7] showed that the survival benefits of surgical treatment in Vp4 patient groups were not statistically significant, and most of them could not achieve R0 or R1 resection. Thus, the authors only recommended liver resection as a first line of treatment when PVTT was limited to the first-order branch of the portal vein. Another large cohort study from China [10] analyzed 1580 patients diagnosed with HCC with PVTT from four of the largest tertiary hospitals. The MSTs of the surgical treatment group for types Ⅰ and Ⅱ patients were 15.9 and 12.5 mo, respectively, and these MSTs were much better compared to their nonsurgical counterparts. The authors concluded that surgical approaches are the best treatment for type Ⅰ/Ⅱ PVTT patients with good liver function. Likewise, several other studies from Eastern countries also suggested the potential survival benefits of surgical treatment in HCCPVTT patients [1114] ; however, most of these studies suggested that operation is not useful for type Ⅳ PVTT patients who had a poor prog nosis.
Surgical vs TACE treatment
Transcatheter arterial chemoembolization (TACE) is commonly used to help patients with advanced HCC including PVTT. Recently, many studies reported that surgical treatment had a better prognosis compared to those undergoing TACE, especially for Cheng's types Ⅰ and Ⅱ PVTT. Peng et al [15] compared 201 HCC patients with PVTT who received surgical treatment and 402 matched cases treated with TACE. The median survival of the surgical treatment and TACE groups was 20.0 mo ± 1.8 mo and 13.1 mo ± 0.6 mo, respectively. The 1, 3, and 5year overall survival rates for the surgical and TACE groups were 42.0%, 14.1%, and 11.1% and 37.8%, 7.3%, and 0.5%, respectively (P < 0.001). The survival curve for the operation group was better than that for the TACE group. Subgroup analyses showed that the overall survival for the operation group was better than that of the TACE group for type Ⅰ/Ⅱ PVTT but not for type Ⅲ/Ⅳ PVTT. This result was concordant with a stratified meta-analysis [16] . Other typical studies [10, 17] also favor the surgical treatment, which showed that the sur vival rates were better for the surgical resection group than the TACE group for Cheng's type Ⅰ/Ⅱ PVTT. Combining preoperative TACE with surgical resection alone was also compared by Yamamoto [18] and Ban [19] ; neither were able to find a survival benefit with pre operative TACE for HCCPVTT patients, especially for Cheng's types Ⅲ and Ⅳ PVTT.
Surgical vs sorafenib treatment
In Western countries, the first-line treatment option for HCCPVTT is sorafenib, but the MST was short at 6.5 mo in the Eastern countries [20] and 10.7 mo in West ern areas [3] . In a study by Jeong et al [21] , 30 patients with HCCPVTT (Vp3 or Vp4) treated with sorafenib mono therapy had a median survival period of only 3.1 mo. Another typical study by Nakazawa et al [22] also revealed that the MST(4.3 mo) was similar for PVTT in the main trunk or in the first branch after treated with sorafenib alone. These data demonstrated that the MST was quite shorter for HCCPVTT treated with surgical method.
SURGICAL CLASSIFICATION
The tumor extent and the range and position of PVTT affect surgical planning and correlate with overall survival after surgical resection. Thus, the surgical method should aim to achieve a complete resection of the primary tumor and removal of PVTT with a sufficient future remnant liver. Therefore, classification of PVTT is necessary to determine the surgical process. Currently, there are two classifications that are well accepted and widely used in the Asia-Pacific: the Japanese Vp classification [23, 24] and the classification suggested by
Cheng, who is a Chinese professor [12, 25] .
Japanese classification
The Liver Cancer Study Group of Japan proposed a help ful macroscopic classification divided into five grades (Vp0Vp4) [23, 25] for HCC with PVTT. Each one is defined as follows: (1) no tumor thrombus in the portal vein, Vp0; (2) existence of a tumor thrombus distal to, but not in, the 2ndorder branches of the portal vein, Vp1; (3) presence of a tumor thrombus in the 2ndorder branches of the portal vein, Vp2; (4) existence of a tumor thrombus in the 1storder branches of the portal vein, Vp3; and (5) presence of a tumor thrombus in the main trunk of the portal vein or a portal vein branch contralateral to the mainly involved lobe (or both), Vp4.
Cheng's classification
Cheng's new classification system comprises five grades: Most Japanese studies concluded that surgical treatment did not achieve a better survival outcome compared to nonsurgical treatments in Vp4 PVTT. There are, however, disadvantages of the two classifications: (1) both of them do not consider liver function or tumorcorrelated factors, such as tumor number and size; and (2) no pathological information of PVTT is described, such as necrotic degree, proliferative type, necrotic type and organized type. Several studies recognized that the Cheng's classification was more applicable than the Vp classification for disease assessment and treatment.
SURGICAL METHODS AND EFFICACY
Based on the two classifications, several surgical resection methods and techniques were introduced.
Tumor thrombus lies within the liver resection line
En bloc resection of PVTT with the tumor could be achieved: (1) Segmental hepatectomy is suitable for Vp4 or Types Ⅲ and Ⅳ patients with HCC and PVTT. Shi et al [25] compared the surgical effects of Type Ⅰ/Ⅱ and Type Ⅲ/Ⅳ PVTT and found that the overall survival and diseasefree survival rates of patients with type Ⅲ or Ⅳ PVTT were significantly worse than those of type Ⅰ or Ⅱ. The 1 and 3year overall survival and disease free survival rates of 78 Type Ⅲ patients were 24.7% and 3.6% and 3.0% and 0%, respectively. The 1 and 3year overall survival and diseasefree survival rates of 20 Type Ⅳ patients were 18.0% and 0% and 0% and 0%, respectively. In Li's report [27] , the 1, 3, and 5year OS and DFS rates for the patients whose PVTT extended beyond the resection line were 42.6%, 11.4%, and 5.7% and 15.4%, 5.1%, and 5.1%, respectively.
We analyzed these reports and found that almost all of them performed the thrombectomy after the liver resection. Only Daisuke [19] performed the removal of PVTT prior to the mobilization and transection of the liver, and the MST and OS were much higher than those of the other studies. The MST of 19 Vp4 patients was 28 mo and the 3 and 5year overall survival rates were 41.8% and 20.9%, respectively. The MST of 26 Vp3 patients was 18 mo and the 3 and 5year overall survival rates were 25.2% and 21.2%, respectively.
Efficacy of "thrombectomy first" instead of "liver resection first"
We have performed surgical treatments for Types Ⅲ and Ⅳ PVTT since 2003, and we proposed a "thrombectomy first" surgical concept to provide superior surgical therapeutic effects and simplify the management approach. The tumor thrombus in the main portal vein, the bifur cation or the contralateral portal vein would be removed prior to liver resection. The main advantages of this concept are as follows: (1) Compression and crushing of PVTT during the operative process could be avoided; thus, new intrahepatic metastases caused by tumor scattering from the PVTT to the remnant liver were mini mized; (2) The contralateral portal venous flow could be recovered at an early stage of the operation, which is a beneficial measure for the preservation of remnant liver function; and (3) The portal venous pressure decreases as a result of complete removal of tumor thrombus.
The following considers a right hemihepatectomy as an example to explain the detailed surgical process. The main portal vein (MPV) and the right portal vein (RPV) were clearly revealed by dissecting the fascia and Glisson sheath along the right edge of the hepatoduodenal liga ment until the point where it entered the right liver. The tissues in the front were then pushed forward to fully ex pose the anterior wall of the RPV. Both the right hepatic artery (HA) and the right hepatic duct (HD) were then cut and ligated separately with a 1 cm distance from the entry point of the right liver ( Figure 1A and B) . The right HA and right HD along with the anterior tissues of the Glisson sheath was called the hepatic arteryduct flap (HA-HD flap) (Figures 2 and 3) . The left hepatic portal vein was revealed by pulling up and dissecting the flap, and a small branch of the portal vein that entered the caudate lobe was cut and ligated in this process. The Japanese classification Vp12 or Cheng's classification Type Ⅰ; (2) Hemihepatectomy is suitable for Japanese classification Vp3 or Cheng's classification Type Ⅱa, and the primary tumor should be located in the same liver without extending beyond the hemiliver; and (3) Extended hemihepatectomy is suitable for Cheng's clas sification Type Ⅱb and Japanese classification Vp4 (tumor thrombus in the bifurcation of the portal vein).
Tumor thrombus lies beyond the liver resection line
Hepatectomy plus thrombectomy or en bloc resection (with or without reconstruction of the main portal vein) can be selected in this kind of HCCPVTT, which includes Japanese classification Vp4 and Cheng's classification Types Ⅲ and Ⅳ. The PVTT is typically extracted through an incision in the portal vein after resection to the liver.
Tumor thrombus invades the main portal vein wall
Combined with the main portal resection, a direct end toend reconstruction is usually needed after the hepa tectomy when the wall of the main portal vein is invaded by the tumor thrombus or if the removal is difficult. However, this concept is not recommended by the study based on the findings of the Japanese registry, and the result showed that when the tumor thrombus lies beyond the liver resection line or invades the main portal vein wall (type Ⅲ/Ⅳ PVTT), there was no significant improvement in survival after surgical treatment.
Efficacy of different surgical methods
Several studies compared the surgical approaches, com plications, survival benefit, and recurrence between hepatectomy with thrombectomy and hepatectomy with en bloc resection. Most of reports showed that hepa tectomy plus thrombectomy or en bloc resection was not significantly different no matter for patients with Vp4 or Vp3 PVTT when compared for overall survival and diseasefree survival at 1, 3, and 5 years, but hepa tectomy had a lower mortality and morbidity [26, 27] . While some other studies suggested that thrombectomy had a risk of residual tumor and hepatectomy plus en bloc resection with or without reconstruction of the main portal vein would theoretically improve the oncological outcomes. Another typical study [28] also revealed that the 5year overall survival and diseasefree survival rates were not significantly decreased in HCC patients with PVTT extended to the bifurcation of the portal vein if en bloc resection was selected. However, the decision of such surgical manipulations could be based on various factors including the surgeon's expertise in portal vein resection and reconstruction as well as the nature of the thrombus and no randomized controlled trial had been done to compare these techniques.
"THROMBECTOMY FIRST" INSTEAD OF "LIVER RESECTION FIRST"
Most surgical procedures are "liver resection first"
Most of the studies report that the prognosis is poor for dissection and taping of the RPV, the left portal vein (LPV) and MPV by vascular slings continued prior to ligation of the RPV distant to the bifurcation, followed by clamping of the LPV and MPV distal to the PVTT ( Figure 1C ). The anterior wall of the RPV was opened to a 1 cm distance to the confluence (the incision could be extended to the portal trunk longitudinally if necessary). The PVTT in the RPV and MPV was then extracted from the opening ( Figure  1D ), followed by flushing the potential residual tumor thrombus by the portal vein blood flow by releasing the vascular occlusion band of the MPV. The MPV was occluded again, and the PVTT in the LPV was extracted. The left remnant tumor thrombus was flushed by the reverse portal vein blood through releasing the vascular occlusion band of LPV (the left hepatic artery was not occluded), and a catheter was used to help flushing when necessary. After flushing and confirming that no PVTT remained (Figure 1E ), the stump was closed by a continuous Prolene suture, and the vascular occlusion was released. If the tumor thrombus strongly adhered to the portal vein wall, resection of the portal vein would be required. Direct endtoend anastomosis was conducted to reconstruct the portal vein with the use of a 6/0 Pro lene continuous suture. After suturing, the right liver was mobilized and transected via standard procedure, or the anterior approach was performed using PMOD (Peng' s Multiple Operative Dissector). To achieve longterm survival, the thrombectomy must be completely cleared. A key element to successfully performing the operation is doing so with no time pressure to prevent sloppiness.
When blocking the MPV, the HA blood flow should be not occluded to protect remnant liver function. If the MPV was difficult to dissect, the selected portal vein occlusion method was used by isolating the common hepatic artery and occluding the portal trunk and common hepatic duct together (Figures 4 and 5) .
We have performed the "thrombectomy first" approach at two campuses of the Second Hospital affi liated with Zhejiang University School of Medicine, two campuses of the Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine and Yuebei People's Hospital affiliated with Shantou University School of Medicine for roughly 15 years. Detailed data is still being collected and analyzed (unpublished), but we would like to share three typical Cheng's Type Ⅲ/Ⅳ (Vp4) cases that had longterm survival. The diseasefree sur vival time was 13, 9 and 4.6 years, respectively (Table 1) .
Case 1 ( Figure 6 , the pictures were taken by camera 13 years ago and had poor quality): A 40-year-old man had HBV infection for more than 10 years. The CT scan showed an 8 cm × 6 cm mass with satellite lesions in the right liver, and tumor thrombus was found in the right branch of the portal vein and extended to the MPV, and the liver function was Class A according to Child Pugh classification. The patient was diagnosed with HCCPVTT and received TACE once before surgery. A 50-year-old man had HBV infection for more than 10 years. The CT scan showed a huge mass in the left liver larger than 20 cm × 16 cm, and tumor thrombus was found in the left branch of the portal vein and the main portal vein. The liver function was Child-Pugh Class A. The "thrombectomy first" approach plus left hemihepatectomy was performed in De cember 2013. The patient received antiHBV treatment and TACE once after the operation. He is still alive without recurrence.
We usually classify PVTT as follows: (1) Segmental PVTT (thrombus confined in a segment); (2) Lobar PVTT (thrombus confined in the right/left lobe), which is then subdivided into R lobar and L lobar; (3) Main PVTT (thrombus extending to main trunk portal vein), which is then subdivided into R Main PVTT and L Main PVTT; (4) R + M PVTT (Right PVTT extending to both main trunk and left portal vein); and (5) L + M PVTT (Left PVTT extending to both main trunk and right portal vein). Accordingly, case one belongs to R Main PVTT; case two belongs to R + Main PVTT; case three belongs to L Main PVTT. Our classification seems more helpful for determining the method of surgical intervention when compared with other classifications. It is simpler and easier to remember, and thus, more practical for clinical use.
CONCLUSION
HCC with PVTT is not a surgical contraindication, and the accumulation of experience and development of technology favor surgical treatments. Treatment guide lines led by China and Japan have confirmed the therapeutic effects of surgical treatment in Type Ⅰ/Ⅱ, but the benefit of surgical treatment for Type Ⅲ/Ⅳ is still controversial. Through our experience, we have found that the appropriate surgical approach, especially the new "thrombectomy first" method, would remarkably improve the survival outcomes in patients with Cheng's Ⅲ/Ⅳ PVTT. 
